@ARTICLE{10.3389/fimmu.2020.01326, AUTHOR={Du, Xiaoxiao and Chang, Sheng and Guo, Wenzhi and Zhang, Shuijun and Chen, Zhonghua Klaus}, TITLE={Progress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies}, JOURNAL={Frontiers in Immunology}, VOLUME={11}, YEAR={2020}, URL={https://www.frontiersin.org/articles/10.3389/fimmu.2020.01326}, DOI={10.3389/fimmu.2020.01326}, ISSN={1664-3224}, ABSTRACT={Liver transplantation is currently the most effective method for treating end-stage liver disease. However, recipients still need long-term immunosuppressive drug treatment to control allogeneic immune rejection, which may cause various complications and affect the long-term survival of the recipient. Many liver transplant researchers constantly pursue the induction of immune tolerance in liver transplant recipients, immunosuppression withdrawal, and the maintenance of good and stable graft function. Although allogeneic liver transplantation is more tolerated than transplantation of other solid organs, and it shows a certain incidence of spontaneous tolerance, there is still great risk for general recipients. With the gradual progress in our understanding of immune regulatory mechanisms, a variety of immune regulatory cells have been discovered, and good results have been obtained in rodent and non-human primate transplant models. As immune cell therapies can induce long-term stable tolerance, they provide a good prospect for the induction of tolerance in clinical liver transplantation. At present, many transplant centers have carried out tolerance-inducing clinical trials in liver transplant recipients, and some have achieved gratifying results. This article will review the current status of liver transplant tolerance and the research progress of different cellular immunotherapies to induce this tolerance, which can provide more support for future clinical applications.} }